Andreas Hillenbrand1, Beate Gruener2, Wolfgang Kratzer2, Peter Kern2, Tilmann Graeter3, Thomas F Barth4, Klaus Buttenschoen5, Doris Henne-Bruns6. 1. Department of General and Visceral Surgery, University Hospital Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany. Andreas.Hillenbrand@uniklinik-ulm.de. 2. Department of Internal Medicine, University Hospital Ulm, Ulm, Germany. 3. Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, Germany. 4. Department of Pathology, University Hospital Ulm, Ulm, Germany. 5. Division of General Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada. 6. Department of General and Visceral Surgery, University Hospital Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany.
Abstract
INTRODUCTION: In humans, alveolar echinococcosis (AE) is a serious helminthic disease. Additionally to a long-term medical treatment, in all suitable cases a complete surgical resection with a 20-mm safe distance (minimal distance of larval tissue to resection margin) is recommended. We analyzed the influence of the safe distance and the effect of the postoperative anthelmintic prophylaxis on the long-term outcome of patients who underwent surgery with curative intent. OBJECTIVE: Ninety-two operated patients were evaluated regarding the safe distance, the duration of medical therapy with benzimidazole derivates, and the further course of AE. RESULTS: Median follow-up after surgical procedure was 8.3 years. Twelve patients had a safe distance of 20 mm or more, 16 patients between 10 and 19 mm, 21 patients between 1 and 10 mm, and 10 patients 1 mm. In a further 33 patients, the affected liver was resected without any safe distance. Recurrence of AE was seen in 15 patients between 4 months and 24 years after initial operation. Safe distances of patients with recurrent disease were: 13 × no safe distance, one patient with 1-mm and one patient with 13-mm safe distance. In all patients except one with recurrent AE, postoperative therapy with benzimidazole derivates was stopped. CONCLUSION: A safe distance of at least 1 mm in combination with medical anthelmintic treatment continuing for two years might offer a good chance of being disease-free long term, but the exact period of medical treatment needed is not defined. The therapy regime should be determined through an interdisciplinary approach in specialized centers.
INTRODUCTION: In humans, alveolar echinococcosis (AE) is a serious helminthic disease. Additionally to a long-term medical treatment, in all suitable cases a complete surgical resection with a 20-mm safe distance (minimal distance of larval tissue to resection margin) is recommended. We analyzed the influence of the safe distance and the effect of the postoperative anthelmintic prophylaxis on the long-term outcome of patients who underwent surgery with curative intent. OBJECTIVE: Ninety-two operated patients were evaluated regarding the safe distance, the duration of medical therapy with benzimidazole derivates, and the further course of AE. RESULTS: Median follow-up after surgical procedure was 8.3 years. Twelve patients had a safe distance of 20 mm or more, 16 patients between 10 and 19 mm, 21 patients between 1 and 10 mm, and 10 patients 1 mm. In a further 33 patients, the affected liver was resected without any safe distance. Recurrence of AE was seen in 15 patients between 4 months and 24 years after initial operation. Safe distances of patients with recurrent disease were: 13 × no safe distance, one patient with 1-mm and one patient with 13-mm safe distance. In all patients except one with recurrent AE, postoperative therapy with benzimidazole derivates was stopped. CONCLUSION: A safe distance of at least 1 mm in combination with medical anthelmintic treatment continuing for two years might offer a good chance of being disease-free long term, but the exact period of medical treatment needed is not defined. The therapy regime should be determined through an interdisciplinary approach in specialized centers.
Authors: Alexander Schweiger; Rudolf W Ammann; Daniel Candinas; Pierre-Alain Clavien; Johannes Eckert; Bruno Gottstein; Nerman Halkic; Beat Muellhaupt; Bettina Mareike Prinz; Juerg Reichen; Philip E Tarr; Paul R Torgerson; Peter Deplazes Journal: Emerg Infect Dis Date: 2007-06 Impact factor: 6.883
Authors: Lars Husmann; Hannes Gruenig; Caecilia S Reiner; Ansgar Deibel; Bruno Ledergerber; Virginia Liberini; Stephan Skawran; Urs J Muehlematter; Michael Messerli; Barbara Hasse; Beat Muellhaupt; Martin W Huellner Journal: Sci Rep Date: 2022-07-06 Impact factor: 4.996
Authors: Andreas Hillenbrand; Annika Beck; Wolfgang Kratzer; Tilmann Graeter; Thomas F E Barth; Julian Schmidberger; Peter Möller; Doris Henne-Bruns; Beate Gruener Journal: Langenbecks Arch Surg Date: 2018-06-16 Impact factor: 3.445
Authors: Balázs Dezsényi; Zsolt Dubóczki; Tamás Strausz; Eszter Csulak; Veronika Czoma; Zsolt Káposztás; Mária Fehérvári; Áron Somorácz; András Csilek; Attila Oláh; Kálmán Almási; Attila Patonai; Dénes Görög; Zoltán Széll; Zoltán Tolnai; Tamás Sréter; József Danka; Herbert Auer; Beate Grüner; Thomas F E Barth; Adriano Casulli Journal: BMC Infect Dis Date: 2021-02-10 Impact factor: 3.090